6876-00-2Relevant academic research and scientific papers
BTK Inhibitors and uses thereof
-
Paragraph 1667-1672, (2020/05/02)
The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.
BENZOSULFONYL COMPOUNDS
-
Paragraph 00459, (2019/03/12)
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
Anthracene compound, preparing method of anthracene compound and organic light-emitting device
-
Paragraph 0121-0126, (2017/05/02)
The invention provides an anthracene compound. The anthracene compound has a structure in the formula (I), wherein Q is the C1-60 alkyl group or the C6-60 aryl group or the C5-60 condensed ring group or the C5-60 heterocyclic group; Ar is the C6-60 aryl group or the C5-60 condensed ring group or the C5-60 heterocyclic group; and Ar1 is H, the C1-60 alkyl group, the C1-60 alkoxy group, the C1-60 ether group, the C6-60 aryl group, the C6-60 condensed ring group, the C6-60 heterocyclic group and the C6-60 arylamine group. Compared with the prior art, the anthracene compound is connected with an aromatic compound through anthracene, and the Q, Ar and Ar1 groups are introduced, so that a device emits blue light after the organic compound is applied to the organic light-emitting device; and meanwhile, the means that the above groups are used for adjusting the light-emitting wavelength is adopted, the light-emitting efficiency of the organic light-emitting device is high, and the service life is long.
Polycyclic aromatic compound
-
Paragraph 1079; 1080; 1081, (2016/10/08)
The present invention addresses the problem of providing a novel polycyclic aromatic compound and an organic electroluminescent element using the same. The above problem is solved by providing a novel polycyclic aromatic compound in which a plurality of aromatic rings are connected by boron atoms, oxygen atoms, or the like, thereby increasing the number of options for organic EL element materials, and also solved by providing a superior organic EL element using said novel polycyclic aromatic compound as an organic EL element material.
Visible-light-mediated synthesis of diaryl ethers from arylboronic acids and diaryliodonium salts
Liu, Li,Tang, Jiaqi,Qiang, Jian,Li, Jian,He, Mingyang
, p. 261 - 264 (2016/07/06)
With visible-light irradiation, a simple and metal-free photocatalytic system for the synthesis of diaryl ethers from arylboronic acids and diaryliodonium salts has been developed. The reaction proceeded in high yield for a range of different substrates in the presence of eosin Y under mild reaction conditions.
Anchoring of Pd(ii) complex in functionalized MCM-41 as an efficient and recoverable novel nano catalyst in C-C, C-O and C-N coupling reactions using Ph3SnCl
Ghorbani-Choghamarani, Arash,Nikpour, Farzad,Ghorbani, Farshid,Havasi, Forugh
, p. 33212 - 33220 (2015/04/27)
Anchored palladium(ii) in functionalized MCM-41 mesoporous silica was prepared and used as an efficient, recoverable and thermally stable heterogeneous nano catalyst for C-C, C-O and C-N bond formation in cross-coupling reactions in the presence of Ph3SnCl. MCM-41 was prepared trough hydrothermal synthesis using tetraethyl orthosilicate (Si(OC2H5)4) as silica source and cetyltrimethylammonium bromide (CTAB) as a template. The structure of functionalized MCM-41 was studied by FT-IR, XRD, SEM, TEM, TGA, EDS, ICP and BET techniques.
Triphenyltin chloride as a new source of phenyl group for C-heteroatom and C-C bond formation
Iranpoor, Nasser,Firouzabadi, Habib,Elham, Etemadi Davan,Rostami, Abed,Nematollahi, Arash
, p. 123 - 130 (2013/10/01)
Ph3SnCl is introduced as a very suitable source of phenyl group for coupling with phenols, amines, and thiols in the presence of Cu(OAc)2 in Et3N at room temperature to give aryl ethers, amines, and arylthio ethers in high yields. In addition, the application of Ph3SnCl in the Stille coupling of aryl halides in the presence of Pd(0) catalyst in PEG 400 at 110C is discussed.
Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors
Suzuki, Takayoshi,Imai, Keiko,Imai, Erika,Iida, Shinsuke,Ueda, Ryuzo,Tsumoto, Hiroki,Nakagawa, Hidehiko,Miyata, Naoki
experimental part, p. 5900 - 5905 (2009/12/24)
A series of 2-anilinobenzamide derivatives were designed, synthesized and evaluated for their SIRT1-inhibitory activity. Among these, compounds 3 and 5 inhibited SIRT1 activity in enzyme assays and suppressed the growth of Daudi and HCT116 cells.
Organic compounds
-
Page/Page column 25-26, (2008/06/13)
Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I
Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP3 antagonists
Belley, Michel,Gallant, Michel,Roy, Bruno,Houde, Karine,Lachance, Nicolas,Labelle, Marc,Trimble, Laird A.,Chauret, Nathalie,Li, Chun,Sawyer, Nicole,Tremblay, Nathalie,Lamontagne, Sonia,Carriere, Marie-Claude,Denis, Danielle,Greig, Gillian M.,Slipetz, Deborah,Metters, Kathleen M.,Gordon, Robert,Chan, Chi Chung,Zamboni, Robert J.
, p. 527 - 530 (2007/10/03)
A series of novel ortho-substituted cinnamic acids have been synthesized, and their binding activity and selectivity on the four prostaglandin E 2 receptors evaluated. Many of them are very potent and selective EP3 antagonists (Ki 3-10 nM), while compound 9 is a very good and selective EP2 agonist (Ki 8 nM). The biological profile of the EP2 agonist 9 in vivo and the metabolic profile of selected EP3 antagonists are also reported.
